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Chiral cyclometalated iridium complexes for
asymmetric reduction reactions†
Jennifer Smith, Aysecik Kacmaz, Chao Wang, Barbara Villa-Marcos and
Jianliang Xiao *
A series of chiral cyclometalated iridium complexes have been synthesised by cyclometalating chiral
2-aryl-oxazoline and imidazoline ligands with [Cp*IrCl2]2. These iridacycles were studied for asymmetric
transfer hydrogenation reactions with formic acid as the hydrogen source and were found to display
various activities and enantioselectivities, with the most effective ones affording up to 63% ee in the
asymmetric reductive amination of ketones and 77% ee in the reduction of pyridinium ions.
1. Introduction
Cyclometalated Cp*-iridium complexes, or iridacycles, are
easily accessible via base-assisted C–H activation. A number of
such complexes have been documented both within our
group1 as well as by others with various applications.2
Examples of their use as catalysts are seen in hydrogenation,3
transfer hydrogenation,4 dehydrogenation,5 reductive amin-
ation,6 alkylation,7 hydrosilylation,8 racemisation,9 hydroami-
nation10 and aerobic oxidation.11 However, most of these com-
plexes are achiral, and the number of reported chiral irida-
cycles and their applications in asymmetric catalysis is much
smaller.
Chiral iridacycle complexes have been sporadically reported
over the past years. Selected examples are shown in Scheme 1.
Ikariya et al. reported the use of chiral Cp*Ir(C–N) complexes12
for asymmetric transfer hydrogenation (ATH) of acetophenone,
yielding (S)-1-phenylethanol in over 90% yield with up to 66%
ee. Pfeffer and de Vries et al. reported cyclometalated amino
and imidazoline complexes;13 the latter was used for ATH of
acetophenone and N-phenyl-(1-phenylethylidene)amine,
showing moderate to high yields with low enantioselectivities
up to 19% ee.13a Baya et al. also reported the use of cyclometa-
lated iridium complexes for ATH of ketones, affording low to
moderate enantioselectivities (up to 58% ee).14 Davies et al.
synthesised iridacycles bearing a chiral oxazoline ligand.15
Leung et al. carried out ATH of acetophenone with chiral irida-
cycles, providing up to 69% ee at −30 °C.16 In recent years, the
group of Richards have reported a series of planar chiral irida-
cycles bearing ferrocene-type ligands, although their appli-
cation in asymmetric catalysis has rarely been seen.17 More
recently, novel chiral iridacycles have been reported by the
groups of de la Torre, Sierra and Cramer.18 Our group reported
iridium complexes bearing N,O- and N,C-chelating oxazoline
ligands for ATH of aromatic ketones; however, the cyclometa-
lated N,C-complex was much less active and enantioselective
(up to 7% ee) than the N,O-chelated complex (up to 99% ee).19
In continuation of our study into iridacycles, we have syn-
thesised a range of chiral iridium catalysts and examined their
ability in direct asymmetric reductive amination (DARA) of
ketones and reduction of pyridiniums via ATH. Reported
herein is the results of these studies.
2. Results and discussion
2.1. Synthesis of chiral iridacycles
Base-promoted cyclometallation has been widely studied.15,20
The reaction typically involves C–H bond activation of a chiral
Scheme 1 Examples of chiral iridacycles from the literature.
†Electronic supplementary information (ESI) available: Experimental procedures
and compound characterization data. CCDC 2031296 and 2031297. For ESI and
crystallographic data in CIF or other electronic format see DOI: 10.1039/
d0ob02049d
Department of Chemistry, University of Liverpool, Liverpool, L69 7ZD, UK.
E-mail: jxiao@liv.ac.uk




































































































ligand with an iridium precursor to form the cyclometalated
structure. In 1998, Beck et al.20b reported iridacycles being pro-
duced from the reaction of [Cp*IrCl2]2 with substituted
2-phenyl-4-R-5(4H)-oxazolones in the presence of NaOAc. In
2003, Davies20c carried out similar cyclometalation of nitrogen-
containing ligands with [Cp*IrCl2]2, [Cp*RhCl2]2 and [RuCl2(p-
cymene)]2, revealing the assisting role of the acetate. In most
subsequent studies, a similar strategy has been deployed.
To access the chiral iridacycles in this study, a range of
ligands consisting of chiral oxazoline and imidazoline motifs
were prepared. These were easily accessible from the reaction
between a benzaldehyde derivative and a chiral amino alcohol
or diamine, using reported methods (Scheme 2).21 The sub-
sequent cyclometalation of the iridium precursor [Cp*IrCl2]2
with the chiral oxazoline and imidazoline ligands generally
occurred under mild conditions, affording the chiral irida-
cycles 1–15 (Scheme 2). However, more forcing conditions were
required for some iridacycles, e.g. 4, likely due to the increased
steric hindrance in the ligands.
The formation of the iridacycles was confirmed by NMR
and HRMS analysis and by X-ray diffraction in the case of com-
plexes 1 and 2. Chelation of the ligands onto iridium intro-
duces chirality at the metal centre. However, the iridacycles are
formed generally as a mixture of two diastereoisomers, pre-
sumably due to the small difference between their thermo-
dynamic stability, as has been observed in analogous
cases.13,20c For example, 1 and 2 exist as a 2 : 1 and
1 : 1 mixture, respectively, in chloroform. The X-Ray diffraction
structures of 1 and 2 (Fig. 1) were obtained from single crystals
by diffusing n-hexane into a dichloromethane solution of the
complexes. As expected, piano-stool style geometries are
observed for both complexes. The structure of 1, which bears
the cis- or (S,R)-oxazoline ligand, features a S-configured
iridium centre in the solid state. In contrast, the iridium
centre of 2, which bears the trans- or (R,R)-oxazoline ligand, is
R-configured. The bond distances involving the iridium show
no notable difference between the two complexes except for a
slightly longer Ir–N distance in 2 and are in the expected
range. A CH/π interaction appears present between the methyl
Fig. 1 Molecular structures of 1 and 2 determined by single crystal
X-ray diffraction. For 1: selected bond distances (Å): Ir1–Cl1 2.402(1),
Ir1–N1 2.084(2), Ir1–C10 2.052(3). Selected bond angles (°): Cl1–Ir1–N1
85.1(1), Cl1–Ir1–C10 83.2(1), N1–Ir1–C10 77.4(2). For 2: selected bond
distances (Å): Ir1–Cl1 2.4056(6), Ir1–N1 2.101(2), Ir1–C17 2.062. Selected
bond angles (°): Cl1–Ir1–N1 86.57(5), Cl1–Ir1–C17 84.18, N1–Ir1–C17
77.48(8).
Scheme 2 Synthesis of oxazoline and imidazoline ligands and related
chiral iridacycles.
Table 1 Screening of iridacycles for DARA
Entry İridacycle Conv. (%) ee (%) Entry İridacycle Conv. (%) ee (%)
1 1 68 23 9 9 78 56
2 2 83 14 10a 9 92 56
3 3 62 10 11 10 72 50
4 4 60 0 12 11 75 42
5 5 95 25 13 12 78 21
6 6 50 30 14 13 75 39
7 7 50 17 15 14 65 43
8 8 80 30 16 15 75 43
Reaction conditions: 0.5 mmol acetophenone, 0.6 mmol p-methoxy aniline, 1 mol% iridacycle, 2.5 mL anhydrous IPA, 0.5 mL FT, sealed in air,
ambient temperature; PMP: p-methoxyphenyl. The product is of R configuration. aOptimization at 23 °C.
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of the Cp* ring and the phenyl ring from the oxazoline. For
example, in 1, the distance between a Cp* hydrogen and the
closest hydrogen on the phenyl ring is only 2.640 Å.
2.2. Asymmetric reductive amination of ketones
Chiral amines have received considerable attention in fine
chemical and pharmaceutical applications.22 DARA represents
a convenient pathway for their synthesis and can be accom-
plished through metal-catalysed, organocatalytic or biocataly-
tic approaches, using a range of hydrogen sources.22c,23 Among
them, DARA reactions utilising hydrogen gas have been the
most widely reported,24 whilst ATH systems,25 exploiting other
hydrogen sources, have remained underdeveloped. DARA via
transfer hydrogenation is, however, highly appealing, as it is
likely to be easier and safer in operation than using hydrogen
gas.
Iridacycles 1–15 were initially screened for the DARA of acet-
ophenone with p-methoxyaniline in isopropanol (IPA), using
formic acid as the hydrogen source in the form of formic acid-
triethylamine azeotrope (FT) (Table 1). All the complexes
showed good to high catalytic activities; however, the enantio-
selectivities varied considerably, ranging from 0 to 56% ee.
There appears to be little correlation between the ee’s and the
ligand structure in general, partially due to the diversity of the
ligand structures. Of those screened, complex 9, a 3,4,5-tri-
methoxy imidazoline iridicycle, yielded the highest enantio-
Table 2 DARA of ketones with amines catalyzed by 9a
Entry Ketone Amine Yieldd (%) eee (%) Entry Ketone Amine Yieldd (%) eee (%)
1 90 56 11 97 97b 0 5b
2 95 50 12 37 82c 53 48c
3 94 80b 54 48b 13 37 84c 55 53c
4 80 54 14 8 42c 52 54c
5 96 56 15 47 53
6 95 56 16 50 65c 62 60c
7 88 34 17 80 97c 16 10c
8 88 63 18 66 94c 14 16c
9 75 84c 38 36c 19 77 93c 17 22c
10 38 76c 63 59c 20 90 93c 10 2c
a Reaction conditions (unless otherwise stated) (i): 0.5 mmol ketone, 0.6 mmol amine, 1 mol% 9, 2.5 ml anhydrous IPA, 0.5 mL FT, sealed in air,
16 h. We assume the products to be of the same configuration, i.e. R. b Reaction conditions (ii): 0.5 mmol ketone, 0.6 mmol amine, 1 mol% 9,
3 mL HCO2Na/HCO2H pH 4.5, 0.3 mL 2-MeTHF, sealed in air, 8 h.
c The same reaction condition with [b] but 16 h. d Yield of isolated product.
eDetermined by HPLC.
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selectivity (56% ee) for the DARA (Table 1, entry 9). Therefore,
9 was subjected to a range of different solvents, additives,
hydride sources and temperatures to determine the optimal
conditions (ESI, Table S1†). Finally, it was determined that
using the FT in IPA at 20–25 °C would provide the best conver-
sion and enantioselectivity (Table 1, entry 10).
Subsequently, a range of ketones and amines were investi-
gated to determine whether the iridacycle 9 could be exploited
for DARA. As can be seen from Table 2, whilst 9 catalysed
efficient reductive amination, affording the amine products
generally in high yields, the enantioselectivities were only
moderate in most cases. More specifically, utilising p-methox-
yaniline as the amine source, the para- and meta-substituted
acetophenones provided very high yields and moderate
enantioselectivities (Table 2, entries 2–6). However, an ortho-
substituted ketone displayed a lower enantioselectivity
(Table 2, entry 7), indicating that the ortho substituent inter-
feres with the enantioselectivity-determining step. Changing R′
to an ethyl or a phenyl group led to enhanced selectivity
(Table 2, entries 8 and 10); however, lengthening the alkyl
group resulted in a lower selectivity (Table 2, entry 9), demon-
strating a limit to the functionalisation that can be tolerated in
this position. The reaction with an alkyl ketone afforded a very
high yield (97%), but racemic amine (Table 2, entry 11). In the
case of other aniline derivatives coupling with acetophenone,
the yields decreased significantly (Table 2, entries 12–16), indi-
cating that the electron donating methoxy group on the amine
is crucial, probably assisting in the imine formation. With the
more nucleophilic benzylamines (Table 2, entries 17–20), the
yields were high; but the enantioselectivity was disappointingly
low, presumably as a result of reduced steric rigidity in the
imine intermediate.
Aiming to improve the yield and enantioselectivity, the
impact of aqueous conditions was also investigated, utilising
NaCO2H/HCO2H(aq.) at pH 4.5 as a hydrogen source for DARA,
with 2-methyltetrahydrofuran (2-MeTHF) as a co-solvent.
Under such conditions, some of the yields were improved;
however, the enantioselectivities showed little change (Table 2,
entries 3, 9–14, 16). In particular, benzylamines afforded
higher yields but still low enantioselectivities (Table 2, entries
17–20).
2.3. ATH of pyridinium salts
Chiral piperidines are valuable building blocks for natural pro-
ducts and synthetic bioactive molecules. Asymmetric hydro-
genation of pyridines can be used to obtain chiral piper-
idines.26 However, these reactions are generally difficult to
carry out, due to the coordination ability and the resonance
stability of the pyridines. To overcome these challenges, pyri-
dines can be activated, in the form of pyridinium salts or
auxiliary-substituted pyridines.26b,27 Whilst transfer hydrogen-
ation of pyridines has been reported,4a,28 very little has been
reported for ATH of pyridines. In 2007 Rueping et al. devel-
oped the first organocatalytic ATH system, utilising a Brønsted
acid to activate the substrate and induce chirality.29 With the
chiral iridacycles in hand, we also examined their potential for
ATH of pyridinium salts.
The iridacycles were first examined for ATH of N-benzyl-2-
phenylpyridinium bromide salt, using FT in IPA, as shown
Table 3. It appears that the oxazoline-containing iridacycles
Table 4 ATH of selected pyridinium salts with 10a






a Reaction conditions: 0.5 mmol pyridinium salt, 1 mol% 10, 5 mL
anhydrous IPA, 1 mL FT, −10 °C, sealed, 16 h. b Yield of isolated
product. cDetermined by HPLC; configuration unknown. PMP:
p-methoxyphenyl.
Table 3 Screening iridacycles for ATH of pyridinium salt
Entry Iridacycle ee (%) Entry Iridacycle ee %
1 3 20 8 10 51
2 4 10 9a 10 77(97)b
3 5 15 10 11 33
4 6 6 11 12 24
5 7 34 12 13 20
6 8 25 13 14 46
7 9 44 14 15 38
Reaction conditions: 0.5 mmol pyridinium salt, 1 mol% Ir cat, 2.5 mL
anhydrous IPA, 0.5 mL FT, sealed, ambient temperature. Enantiomeric
excess determined by chiral HPLC. a Reaction conducted at −10 °C.
b Isolated yield in parentheses.
Paper Organic & Biomolecular Chemistry



































































































(Table 3, entries 1–6,) generally exhibited a low enantio-
selectivity (up to 34% ee). Among the imidazoline ligands, the
previously used 9 provided 44% ee, and the best enantio-
selectivity was achieved with the dioxoleiridacycle 10, which
afforded 51% ee (Table 3, entry 8). Using 10 as catalyst at a
lower temperature of −10 °C, the selectivity was increased and
the piperidine was isolated in 97% yield with an ee of 77%
(Table 3, entry 9)
Under the conditions identified, we examined the ATH of a
range of pyridinium salts. Selected examples are shown in
Table 4.‡ As can be seen, the iridacycle 10 is active for the sub-
stituted pyridinium salts, affording the corresponding piper-
idines in high yields. However, the enantioselectivity varied
considerably, from 77% ee for the 2-aryl substituted substrates
to 10% ee for the less sterically hindered 2-benzyl substituted
one (Table 4, entries 1–3).
3. Conclusions
Chiral iridacycles can be easily accessed via cyclometalation
reaction of [Cp*IrCl2]2 with a ligand that undergoes C–H acti-
vation and such complexes could serve as catalysts for asym-
metric reactions. In this study, we have synthesised a wide
range of chiral iridacycles and examined their potential appli-
cation in DARA via transfer hydrogenation. Among the irida-
cycles, the 3,4,5-trimethoxy imidazoline-bearing 9 proved to be
the most effective, affording moderate enantioselectivities in
the DARA of acetophenones with aniline derivatives. The irida-
cycles are also active in catalysing the ATH of pyridiniums,
albeit with only good ee’s in the case of 2-aryl substituted sub-
strates. Research within our group continues to develop chiral
iridacycles, aiming for better enantioselective catalysts.
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